EBQ:ProMISe Trial: Difference between revisions
Neil.m.young (talk | contribs) No edit summary |
Ostermayer (talk | contribs) |
||
(11 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
| title= Trial of Early, Goal-Directed Resuscitation for Septic Shock | | title= Trial of Early, Goal-Directed Resuscitation for Septic Shock | ||
| abbreviation= ProMISe Trial | | abbreviation= ProMISe Trial | ||
| expansion= Protocolised Management In Sepsis | |||
| published= April 2, 2015 | | published= April 2, 2015 | ||
| author= Mouncey PR, Osborn TM, Power GS, et al | | author= Mouncey PR, Osborn TM, Power GS, et al | ||
Line 12: | Line 13: | ||
| fulltexturl= http://www.nejm.org/doi/full/10.1056/NEJMoa1500896 | | fulltexturl= http://www.nejm.org/doi/full/10.1056/NEJMoa1500896 | ||
| pdfurl= | | pdfurl= | ||
| status=Complete | |||
}} | }} | ||
==Clinical Question== | ==Clinical Question== | ||
Line 17: | Line 19: | ||
==Conclusion== | ==Conclusion== | ||
Using EGDT did not lead to an improved outcomes. | |||
==Major Points== | ==Major Points== | ||
*Mortality was no different at 90-days 29.5% vs 29.2% | |||
*Slight increase is SOFA score at the first 6 hours in the EGDT group (assessment of organ dysfuction) | |||
*Slight increase in length of stay in the ICU | |||
==Study Design== | ==Study Design== | ||
Pragmatic, open, multicenter, parallel-group, randomized, controlled trial | |||
==Population== | ==Population== | ||
56 hospitals in the UK | 56 hospitals in the UK from Feb 2, 2011 to Jul 24, 2014 (29% teaching hospitals) | ||
===Patient Demographics=== | ===Patient Demographics=== | ||
*Highlights | |||
**Only significant difference was age (66.4 vs 64.3) | |||
**~58% male | |||
**~55% had refractory hypotension | |||
**~64% had hyperlactatemia | |||
===Inclusion Criteria=== | ===Inclusion Criteria=== | ||
*≥18 years of age | *≥18 years of age | ||
Line 34: | Line 46: | ||
===Exclusion Criteria=== | ===Exclusion Criteria=== | ||
* | *Age <18yrs | ||
* | *Known pregnancy | ||
* | *Primary diagnosis of: | ||
*Acute pulmonary edema | **CVA, Acute pulmonary edema, Status asthmaticus, Major cardiac arrhythmia, Seizure, Drug overdose, Burn or trauma | ||
*GI | *GI bleeding | ||
* | *Known AIDS | ||
* | *Requirement for immediate surgery | ||
* | *DNR or advanced directives restricting the protocol | ||
* | *Contraindication to central line or blood transfusion | ||
* | *Transfer | ||
* | |||
* | ==Interventions== | ||
* | *Radomization within 2 hours after meeting criteria | ||
* | ===Group 1 – EGDT (n=623)=== | ||
*Airway/breathing | |||
*Central line with oximetric port | |||
*Sedation, analgesia, and/or paralysis | |||
*IVF per CVP | |||
*Vasoactive agents per MAPs | |||
*Transfusion and inotrope agents per ScvO2 | |||
*Reassess | |||
===Group 2 – Usual Care (n=620)=== | |||
*Typical care provided at clinician's discretion | |||
*Restricted usag of ScvO2 monitoring | |||
==Outcomes== | ==Outcomes== | ||
===Primary Outcome=== | ===Primary Outcome=== | ||
*All-cause mortality at 90 days | |||
**29.5% vs 29.2% (p=0.90) | |||
===Secondary Outcomes=== | ===Secondary Outcomes=== | ||
====Findings with Significant Differences==== | |||
*SOFA score at 6hr | |||
**6.4 vs 5.6 (p<0.001) | |||
*Receipt of advanced cardiac support | |||
**37.0 vs 30.9 (p=0.026) | |||
*LOS in ICU | |||
**2.6 vs 2.2 (p=0.005) | |||
=== | ====Findings with Non Significant Differences==== | ||
*SOFA score at 72hrs | |||
*Receipt of advanced respiratory, or renal support and when it started | |||
*Days free of the above advance support | |||
*LOS in ED and hospital | |||
*Duration of survival | |||
*All-cause mortality at 28 days, hospital discharge, and 1yr | |||
*Health related quality of life, resource use, and cost at 90d and 1yr | |||
==Criticisms & Further Discussion== | ==Criticisms & Further Discussion== | ||
*There was a trend towards being more cost effective with usual-care ($17,647 vs $16,239, p=0.26). | |||
*The usual-care group still had a large portion of arterial lines and central lines. If we eliminate ScvO2 monitoring, the protocol becomes essentially guidelines for care. | |||
*Expected mortality in this group 40% while actual mortality was 29%. This matches closely with the 30.5% found in the Rivers 2001 EGDT Trial. This is the first time these numbers have been replicated as the US ProCESS Trial had a mortality rate of 18.9% at 60 days (compared to 30-46% as expected) and the Australia/New Zealand ARISE Trial had mortality 18.8% at 90 days (compared to 38% anticipated). | |||
==External Links== | ==External Links== | ||
Line 71: | Line 103: | ||
==Funding== | ==Funding== | ||
The NIHR Health Technology Assessment (HTA) Programme (07/37/47) is supported the central coordination of the trial through the ICNARC CTU, and the local site start up costs. This includes dedicated local research nurses and the economic evaluation. | |||
==See Also== | |||
*[[Sepsis]] | |||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:EBQ]] | [[Category:EBQ]][[Category:Critical Care]] |
Latest revision as of 23:25, 26 February 2016
Complete Journal Club Article
Mouncey PR, Osborn TM, Power GS, et al. "Trial of Early, Goal-Directed Resuscitation for Septic Shock". NEJM. 2015. 14(372):1301-1311.
PubMed Full text
PubMed Full text
Clinical Question
Is there a different between EGDT versus “usual care” in 90-day mortality?
Conclusion
Using EGDT did not lead to an improved outcomes.
Major Points
- Mortality was no different at 90-days 29.5% vs 29.2%
- Slight increase is SOFA score at the first 6 hours in the EGDT group (assessment of organ dysfuction)
- Slight increase in length of stay in the ICU
Study Design
Pragmatic, open, multicenter, parallel-group, randomized, controlled trial
Population
56 hospitals in the UK from Feb 2, 2011 to Jul 24, 2014 (29% teaching hospitals)
Patient Demographics
- Highlights
- Only significant difference was age (66.4 vs 64.3)
- ~58% male
- ~55% had refractory hypotension
- ~64% had hyperlactatemia
Inclusion Criteria
- ≥18 years of age
- Within 6 hours of presenting to ED
- Known or presumed infection
- 2 or more SIRS criteria
- Refractory hypotension (<90 SBP or <65 MAP after 1L IVF trial) or hyperlactatemia (≥4.0)
Exclusion Criteria
- Age <18yrs
- Known pregnancy
- Primary diagnosis of:
- CVA, Acute pulmonary edema, Status asthmaticus, Major cardiac arrhythmia, Seizure, Drug overdose, Burn or trauma
- GI bleeding
- Known AIDS
- Requirement for immediate surgery
- DNR or advanced directives restricting the protocol
- Contraindication to central line or blood transfusion
- Transfer
Interventions
- Radomization within 2 hours after meeting criteria
Group 1 – EGDT (n=623)
- Airway/breathing
- Central line with oximetric port
- Sedation, analgesia, and/or paralysis
- IVF per CVP
- Vasoactive agents per MAPs
- Transfusion and inotrope agents per ScvO2
- Reassess
Group 2 – Usual Care (n=620)
- Typical care provided at clinician's discretion
- Restricted usag of ScvO2 monitoring
Outcomes
Primary Outcome
- All-cause mortality at 90 days
- 29.5% vs 29.2% (p=0.90)
Secondary Outcomes
Findings with Significant Differences
- SOFA score at 6hr
- 6.4 vs 5.6 (p<0.001)
- Receipt of advanced cardiac support
- 37.0 vs 30.9 (p=0.026)
- LOS in ICU
- 2.6 vs 2.2 (p=0.005)
Findings with Non Significant Differences
- SOFA score at 72hrs
- Receipt of advanced respiratory, or renal support and when it started
- Days free of the above advance support
- LOS in ED and hospital
- Duration of survival
- All-cause mortality at 28 days, hospital discharge, and 1yr
- Health related quality of life, resource use, and cost at 90d and 1yr
Criticisms & Further Discussion
- There was a trend towards being more cost effective with usual-care ($17,647 vs $16,239, p=0.26).
- The usual-care group still had a large portion of arterial lines and central lines. If we eliminate ScvO2 monitoring, the protocol becomes essentially guidelines for care.
- Expected mortality in this group 40% while actual mortality was 29%. This matches closely with the 30.5% found in the Rivers 2001 EGDT Trial. This is the first time these numbers have been replicated as the US ProCESS Trial had a mortality rate of 18.9% at 60 days (compared to 30-46% as expected) and the Australia/New Zealand ARISE Trial had mortality 18.8% at 90 days (compared to 38% anticipated).
External Links
Funding
The NIHR Health Technology Assessment (HTA) Programme (07/37/47) is supported the central coordination of the trial through the ICNARC CTU, and the local site start up costs. This includes dedicated local research nurses and the economic evaluation.